Microbot Medical Inc. (NASDAQ:MBOT) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Microbot Medical Inc. (NASDAQ:MBOT) have been given a consensus rating of “Moderate Buy” by the five research firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $7.50.

Several research firms recently issued reports on MBOT. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Microbot Medical in a research report on Friday, November 28th. Roth Mkm assumed coverage on Microbot Medical in a research report on Wednesday, December 3rd. They issued a “buy” rating and a $5.50 price objective for the company. Finally, B. Riley Financial assumed coverage on Microbot Medical in a research note on Tuesday, February 10th. They set a “buy” rating for the company.

Microbot Medical Stock Down 1.5%

Microbot Medical stock opened at $2.69 on Friday. The firm has a fifty day simple moving average of $2.16 and a two-hundred day simple moving average of $2.51. Microbot Medical has a twelve month low of $1.35 and a twelve month high of $4.67. The company has a market capitalization of $180.66 million, a PE ratio of -5.98 and a beta of 1.22.

Institutional Investors Weigh In On Microbot Medical

Institutional investors have recently added to or reduced their stakes in the company. Cornerstone Advisory LLC bought a new stake in Microbot Medical in the 3rd quarter worth $30,000. American Century Companies Inc. bought a new position in shares of Microbot Medical during the second quarter valued at about $32,000. Zacks Investment Management bought a new position in shares of Microbot Medical during the third quarter valued at about $33,000. Man Group plc bought a new position in shares of Microbot Medical during the fourth quarter valued at about $35,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Microbot Medical during the third quarter worth about $37,000. Hedge funds and other institutional investors own 16.30% of the company’s stock.

About Microbot Medical

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.